BIO-Europe 2026
Talk Presenting Companies (Theatre A) track
Immuno-Oncology: Progeneer
Mon, Nov 9, 2026 · 3:00–3:15 PM CET Koelnmesse
About this session
Progeneer is a biotechnology company developing next-generation immunotherapies and cancer vaccines based on its proprietary TLR7/8 agonist platform, ProLNG. ProLNG is a platform technology designed to induce potent and durable anti-tumor immune responses while improving safety and controllability. The platform has broad applicability across multiple cancer indications and therapeutic modalities.
Speaker
-
CEO · Progeneer
Speaker